Skip to main content
Scinai Immunotherapeutics Ltd. (TLV:BVXV)
Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
49.30
-1.00 (-1.99%)
At close: Jan 18, 2018

Scinai Immunotherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Revenue
1.310.66---
Upgrade
Revenue Growth (YoY)
99.24%----
Upgrade
Cost of Revenue
3.961.24---
Upgrade
Gross Profit
-2.65-0.58---
Upgrade
Selling, General & Admin
2.522.534.515.37.63
Upgrade
Research & Development
2.375.535.215.773.25
Upgrade
Other Operating Expenses
---0.01--0.01
Upgrade
Operating Expenses
4.898.069.7111.0610.86
Upgrade
Operating Income
-7.54-8.64-9.71-11.06-10.86
Upgrade
Interest Expense
-0.36-1.42-3.8--
Upgrade
Interest & Investment Income
0.020.13.923.053.15
Upgrade
Currency Exchange Gain (Loss)
-0.42-0.08-0.931.52-0.49
Upgrade
Other Non Operating Income (Expenses)
-0.010.084.020.69-0.01
Upgrade
EBT Excluding Unusual Items
-8.31-9.96-6.5-5.8-8.21
Upgrade
Other Unusual Items
-14.76---
Upgrade
Pretax Income
-8.314.8-6.5-5.8-8.21
Upgrade
Net Income
-8.314.8-6.5-5.8-8.21
Upgrade
Preferred Dividends & Other Adjustments
-4.8---
Upgrade
Net Income to Common
-8.31--6.5-5.8-8.21
Upgrade
Shares Outstanding (Basic)
21000
Upgrade
Shares Outstanding (Diluted)
21000
Upgrade
Shares Change (YoY)
189.55%106.41%107.22%33.56%27.37%
Upgrade
EPS (Basic)
-3.56--16.64-30.74-58.14
Upgrade
EPS (Diluted)
-3.56--16.64-30.74-80.00
Upgrade
Free Cash Flow
-6.06-6.35-10.02-8.1-7.57
Upgrade
Free Cash Flow Per Share
-2.59-7.87-25.65-42.97-53.60
Upgrade
Gross Margin
-202.29%-88.15%---
Upgrade
Operating Margin
-575.29%-1312.77%---
Upgrade
Profit Margin
-633.64%----
Upgrade
Free Cash Flow Margin
-461.86%-964.59%---
Upgrade
EBITDA
-6.12-6.99-9.19-10.5-10.39
Upgrade
D&A For EBITDA
1.421.650.510.560.47
Upgrade
EBIT
-7.54-8.64-9.71-11.06-10.86
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.